Show simple item record

dc.contributor.authorSaunders, EJ
dc.contributor.authorDadaev, T
dc.contributor.authorLeongamornlert, DA
dc.contributor.authorAl Olama, AA
dc.contributor.authorBenlloch, S
dc.contributor.authorGiles, GG
dc.contributor.authorWiklund, F
dc.contributor.authorGronberg, H
dc.contributor.authorHaiman, CA
dc.contributor.authorSchleutker, J
dc.contributor.authorNordestgaard, BG
dc.contributor.authorTravis, RC
dc.contributor.authorNeal, D
dc.contributor.authorPasayan, N
dc.contributor.authorKhaw, K-T
dc.contributor.authorStanford, JL
dc.contributor.authorBlot, WJ
dc.contributor.authorThibodeau, SN
dc.contributor.authorMaier, C
dc.contributor.authorKibel, AS
dc.contributor.authorCybulski, C
dc.contributor.authorCannon-Albright, L
dc.contributor.authorBrenner, H
dc.contributor.authorPark, JY
dc.contributor.authorKaneva, R
dc.contributor.authorBatra, J
dc.contributor.authorTeixeira, MR
dc.contributor.authorPandha, H
dc.contributor.authorGovindasami, K
dc.contributor.authorMuir, K
dc.contributor.authorUK Genetic Prostate Cancer Study Collaborators,
dc.contributor.authorUK ProtecT Study Collaborators,
dc.contributor.authorPRACTICAL Consortium,
dc.contributor.authorEaston, DF
dc.contributor.authorEeles, RA
dc.contributor.authorKote-Jarai, Z
dc.date.accessioned2016-08-16T15:39:32Z
dc.date.issued2016-04-12
dc.identifier.citationBritish journal of cancer, 2016, 114 (8), pp. 945 - 952
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/50
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/bjc.2016.50
dc.description.abstractBACKGROUND: Germline mutations within DNA-repair genes are implicated in susceptibility to multiple forms of cancer. For prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 give rise to moderately elevated risk, whereas two of B100 common, low-penetrance PrCa susceptibility variants identified so far by genome-wide association studies implicate RAD51B and RAD23B. METHODS: Genotype data from the iCOGS array were imputed to the 1000 genomes phase 3 reference panel for 21 780 PrCa cases and 21 727 controls from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. We subsequently performed single variant, gene and pathway-level analyses using 81 303 SNPs within 20 Kb of a panel of 179 DNA-repair genes. RESULTS: Single SNP analyses identified only the previously reported association with RAD51B. Gene-level analyses using the SKAT-C test from the SNP-set (Sequence) Kernel Association Test (SKAT) identified a significant association with PrCa for MSH5. Pathway-level analyses suggested a possible role for the translesion synthesis pathway in PrCa risk and Homologous recombination/Fanconi Anaemia pathway for PrCa aggressiveness, even though after adjustment for multiple testing these did not remain significant. CONCLUSIONS: MSH5 is a novel candidate gene warranting additional follow-up as a prospective PrCa-risk locus. MSH5 has previously been reported as a pleiotropic susceptibility locus for lung, colorectal and serous ovarian cancers.
dc.formatPrint
dc.format.extent945 - 952
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectUK Genetic Prostate Cancer Study Collaborators
dc.subjectUK ProtecT Study Collaborators
dc.subjectPRACTICAL Consortium
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectGenetic Predisposition to Disease
dc.subjectDNA Repair Enzymes
dc.subjectCell Cycle Proteins
dc.subjectDNA-Binding Proteins
dc.subjectBRCA1 Protein
dc.subjectDNA
dc.subjectRisk
dc.subjectCase-Control Studies
dc.subjectProspective Studies
dc.subjectDNA Repair
dc.subjectGenotype
dc.subjectGerm-Line Mutation
dc.subjectPolymorphism, Single Nucleotide
dc.subjectGenes, BRCA2
dc.subjectMale
dc.subjectGenome-Wide Association Study
dc.titleGene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
dc.typeJournal Article
dcterms.dateAccepted2016-02-09
rioxxterms.versionofrecord10.1038/bjc.2016.50
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue8
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume114
pubs.embargo.termsNo embargo
icr.researchteamOncogenetics
dc.contributor.icrauthorSaunders, Edward
dc.contributor.icrauthorEeles, Rosalind
dc.contributor.icrauthorKote-Jarai, Zsofia


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0